Navitoclax (ABT-263)

製品コードS1001

Navitoclax (ABT-263)化学構造

分子量(MW):974.61

Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。

サイズ 価格 在庫  
USD 504 あり
USD 151 あり
USD 252 あり
USD 466 あり
USD 1222 あり

文献中の引用(37)

カスタマーフィードバック(13)

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

製品安全説明書

Bcl-2阻害剤の選択性比較

生物活性

製品説明 Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。
靶点
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro試験

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NGf0R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuxfYZjUUN3ME2wMlAxPjZ7IN88US=> NUL4W|BYW0GQR1XS
MV-4-11 M{HqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrlTWM2OD1yLkCxOVg3KM7:TR?= NIX1T3pUSU6JRWK=
NKM-1 NYLiSJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TTN2lEPTB;MD6wNVY6QSEQvF2= NInlR3lUSU6JRWK=
ML-2 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1niVGlEPTB;MD6wNVk5OyEQvF2= MWDTRW5ITVJ?
BV-173 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEKzNVQh|ryP NFrhe3ZUSU6JRWK=
RS4-11 M4XMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEK1PFch|ryP NInjRVlUSU6JRWK=
HL-60 M{TxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD1yLkCyPVA5KM7:TR?= M1nT[3NCVkeHUh?=
KY821 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X4fGlEPTB;MD6wNlk4PSEQvF2= MlfpV2FPT0WU
ECC10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEO3PVIh|ryP Ml21V2FPT0WU
NCI-H720 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHVbHhKSzVyPUCuNFQxOTFizszN Mn7xV2FPT0WU
QIMR-WIL MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm3flRxUUN3ME2wMlA1Ojh5IN88US=> M{nybnNCVkeHUh?=
KG-1 M1HBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzRO5c6UUN3ME2wMlA1PDh4IN88US=> MlnXV2FPT0WU
TGW M3LZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Ub3BzUUN3ME2wMlA1PjN|IN88US=> MV\TRW5ITVJ?
ATN-1 NH;BRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPRPZlKSzVyPUCuNFQ4OzNizszN NXjoU4h[W0GQR1XS
RH-18 NYjNbY06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWwTWM2OD1yLkC2NFQ5KM7:TR?= M1nJPHNCVkeHUh?=
EW-18 NWDoNotxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn0TWM2OD1yLkC2PFQyKM7:TR?= NGnrb|JUSU6JRWK=
NB17 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:3TWM2OD1yLkC3NVI1KM7:TR?= Mk[4V2FPT0WU
SK-NEP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEeyNVMh|ryP M4\2UHNCVkeHUh?=
P12-ICHIKAWA NY\Qe3dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn76TWM2OD1yLkC3O|c5KM7:TR?= NFfmOVZUSU6JRWK=
KARPAS-45 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfEcpBKSzVyPUCuNFc5OTVizszN NES2SGRUSU6JRWK=
EW-3 NXrTbWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDvbVZKSzVyPUCuNFgxPTNizszN NF;Ye5JUSU6JRWK=
NB13 M4C3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqyTWM2OD1yLkC4NlA{KM7:TR?= MnfIV2FPT0WU
NCI-H209 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEi3NFQh|ryP M1TVNnNCVkeHUh?=
NCI-H1092 NX7v[XByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof0TWM2OD1yLkGwNlc2KM7:TR?= MkexV2FPT0WU
NH-12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37NbWlEPTB;MD6xNFc1PCEQvF2= MYPTRW5ITVJ?
697 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;hTWM2OD1yLkGwPFM6KM7:TR?= NFvPOYxUSU6JRWK=
KE-37 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zocWlEPTB;MD6xNVM4KM7:TR?= NH\XWmpUSU6JRWK=
MOLT-4 NXLXPGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUWxOlkh|ryP NWLUT2hxW0GQR1XS
CHP-134 NGTseHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzHS4x[UUN3ME2wMlE3OzB4IN88US=> M4TuUnNCVkeHUh?=
D-283MED NVzycm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD1yLkG3Olg3KM7:TR?= MXLTRW5ITVJ?
LU-135 NVPFdZBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrhcnVKSzVyPUCuNVg2PTJizszN M3jlOXNCVkeHUh?=
LU-134-A NUjiO2xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;pO2lEPTB;MD6xPFY4OSEQvF2= NWDiSlBEW0GQR1XS
EM-2 NWXOPG1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTRcIZKSzVyPUCuNVk6OThizszN NW\2e|hiW0GQR1XS
LU-139 NXrScVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HHW2lEPTB;MD6yNFQ6QCEQvF2= NIXyRopUSU6JRWK=
ALL-PO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLLTWM2OD1yLkKxPVg5KM7:TR?= NWCwcI5uW0GQR1XS
NB12 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\FXpVMUUN3ME2wMlI{OTF3IN88US=> NWDjTpdLW0GQR1XS
KP-N-YN MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ywPWlEPTB;MD6yN|U4OyEQvF2= NH7IUIdUSU6JRWK=
BEN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMkO5Olgh|ryP MmDGV2FPT0WU
HCC1569 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jre2lEPTB;MD6yOVExPiEQvF2= NVH2NHE6W0GQR1XS
HuO9 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjpTWM2OD1yLkK2O|E2KM7:TR?= NX\3co4{W0GQR1XS
WM-115 NFHsOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnte5M5UUN3ME2wMlI4PzN6IN88US=> NHv4[mdUSU6JRWK=
CCRF-CEM NGG5dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS2XmRIUUN3ME2wMlM{PTJ7IN88US=> NEi3fVdUSU6JRWK=
IST-SL1 M2SyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vTS2lEPTB;MD6zOVM1OyEQvF2= NILFfo1USU6JRWK=
BE-13 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJeJBKSzVyPUCuN|Y1PTlizszN M3O2PXNCVkeHUh?=
COR-L88 NUL2[G1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwM{[1OEDPxE1? MofPV2FPT0WU
DOHH-2 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwNEGwNlMh|ryP MoX2V2FPT0WU
A704 NX21O4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHmTWM2OD1yLkSyOlch|ryP NULyNHpCW0GQR1XS
KNS-81-FD NHnwNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr5RnFzUUN3ME2wMlQ1ODF5IN88US=> NIPtPJpUSU6JRWK=
RPMI-8226 M4W1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTvTWM2OD1yLkS1OlUzKM7:TR?= M{\ITnNCVkeHUh?=
TGBC24TKB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNEW3O|gh|ryP M4fKb3NCVkeHUh?=
NCI-H1304 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED4TXFKSzVyPUCuOFYyPTdizszN Mnr6V2FPT0WU
MOLT-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPhN3d2UUN3ME2wMlQ3PjF|IN88US=> M4PUO3NCVkeHUh?=
EW-22 NI\EOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwNE[2O|Eh|ryP MX;TRW5ITVJ?
MS-1 NETLbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTpc|BKSzVyPUCuOFY6OzNizszN MXzTRW5ITVJ?
RMG-I NWPJ[WVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XVPWlEPTB;MD60PVQ3PCEQvF2= M{\nOnNCVkeHUh?=
NTERA-S-cl-D1 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPLTWM2OD1yLkWwNFE6KM7:TR?= MX3TRW5ITVJ?
NCI-H1048 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNUC5OVMh|ryP NFHjN3VUSU6JRWK=
SW1417 M3T2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsOFFKSzVyPUCuOVU1OzhizszN NHjmTpFUSU6JRWK=
DB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XP[2lEPTB;MD61O|A5KM7:TR?= M4TtVXNCVkeHUh?=
MEG-01 M1rZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDsfIh[UUN3ME2wMlU5OzJizszN Mnn1V2FPT0WU
EW-13 NFLleG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwNUizOFEh|ryP M{P1VnNCVkeHUh?=
LAMA-84 NYjH[WFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv4bW86UUN3ME2wMlU6OjB5IN88US=> NWfXPJBIW0GQR1XS
J-RT3-T3-5 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi3T|NKSzVyPUCuOlA5ODhizszN MX;TRW5ITVJ?
MOLT-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwNkWyOlQh|ryP MnP2V2FPT0WU
DU-4475 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\BTWM2OD1yLk[1OFI4KM7:TR?= M4TBSHNCVkeHUh?=
HAL-01 NFL0c3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ocYlKSzVyPUCuO|I2PDlizszN NYrR[I9sW0GQR1XS
RD NWXqZXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\NeWlEPTB;MD63OVg6QSEQvF2= M1fWXnNCVkeHUh?=
OAW-28 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[1WFBKSzVyPUCuO|g{PyEQvF2= MXfTRW5ITVJ?
HCC38 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jNSGlEPTB;MD64NFE6KM7:TR?= NVXPRpN5W0GQR1XS
NMC-G1 NGq2dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LxXmlEPTB;MD64NVEzOSEQvF2= M3S0OHNCVkeHUh?=
EW-16 MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOEGzNlgh|ryP NEL6OVFUSU6JRWK=
DU-145 NIT2fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwOEm5NlMh|ryP MWDTRW5ITVJ?
HPAF-II NELoV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnldmFKSzVyPUCuPVI3OjhizszN NUKwfWZsW0GQR1XS
A427 M4PkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwOUOwNlIh|ryP M{iwWXNCVkeHUh?=
PA-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLDN|VIUUN3ME2wMlk2PjR{IN88US=> MWTTRW5ITVJ?
OAW-42 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGyTWM2OD1yLkm2NVQ3KM7:TR?= NGnoN3JUSU6JRWK=
L-428 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DTU2lEPTB;MT6wNVI2KM7:TR?= NHfucZJUSU6JRWK=
COLO-824 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMEG3NFgh|ryP NYi1em82W0GQR1XS
P30-OHK M4LZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwMES2PFgh|ryP MWDTRW5ITVJ?
NCI-H2170 M4TuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nlU2lEPTB;MT6wOlI{KM7:TR?= NH35OoJUSU6JRWK=
HCC2998 M1jDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnmbo1oUUN3ME2xMlA4OTN3IN88US=> NXnN[5JtW0GQR1XS
NB14 NHLiZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3uTWM2OD1zLkGzO|Q5KM7:TR?= NXPH[nc6W0GQR1XS
TGBC1TKB NVHGT|RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:2eY01UUN3ME2xMlE1OTV{IN88US=> M3fL[3NCVkeHUh?=
KP-N-YS NIrHOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn5VI5NUUN3ME2xMlE3OjN4IN88US=> M4CxTHNCVkeHUh?=
CAL-120 M4XleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;icGlEPTB;MT6xOlQzQSEQvF2= MWLTRW5ITVJ?
SBC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwMUmwOVMh|ryP NX3iXpV2W0GQR1XS
C32 NEDCdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OzemlEPTB;MT6xPVA5QCEQvF2= NF;QT2VUSU6JRWK=
HCC2157 NYrkb214T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMUm0PVQh|ryP M{Da[nNCVkeHUh?=
COLO-792 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwMkCwO|Eh|ryP M{fFeHNCVkeHUh?=
ES7 M2T1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDoTWM2OD1zLkK3PVUyKM7:TR?= MWDTRW5ITVJ?
HEL NGTtZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6yUJNKSzVyPUGuN|ExOjlizszN MmDXV2FPT0WU
ES4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXESJBKSzVyPUGuN|Q6QThizszN NXy0ZXFPW0GQR1XS
NCI-SNU-1 MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KwfmlEPTB;MT6zOlU2PSEQvF2= NYnkRVhRW0GQR1XS
MDA-MB-415 NVK1dmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXYXYVKUUN3ME2xMlM5QDVizszN NFTFfoFUSU6JRWK=
NCI-H2342 NWS0[IJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPCZ|dKSzVyPUGuOFAzPjlizszN NYjhZ|Z1W0GQR1XS
NB69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnCe4hKSzVyPUGuOFYzPzFizszN M2fMbHNCVkeHUh?=
D-247MG M4TUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LQTWlEPTB;MT61NVEzOiEQvF2= MXrTRW5ITVJ?
SCC-4 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLc2lEPTB;MT61PVg5PyEQvF2= NX\HUFFNW0GQR1XS
HuH-7 NHLmOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLLTWM2OD1zLk[3Nlk{KM7:TR?= MmTFV2FPT0WU
A388 M4C0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X3UmlEPTB;MT62PFczPCEQvF2= MkHBV2FPT0WU
Calu-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwN{C2PVch|ryP MorpV2FPT0WU
NCI-H1648 NVHwXXZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITMZ21KSzVyPUGuO|E1OThizszN NYi0UmN5W0GQR1XS
NCI-H2052 NVLXRYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwN{KyNFEh|ryP MljyV2FPT0WU
Ramos-2G6-4C10 NHfyZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPWfGNKSzVyPUGuO|M3PTZizszN NVjQRo5XW0GQR1XS
DEL NX[3eYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwN{S2PVIh|ryP MVXTRW5ITVJ?
SNU-423 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwN{ixOVch|ryP MlvrV2FPT0WU
COR-L23 NWXQOJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvDdG9KSzVyPUGuO|k5PzRizszN M3vDVXNCVkeHUh?=
OMC-1 M3nq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPxdYFYUUN3ME2xMlg3ODF4IN88US=> NXz2OGFCW0GQR1XS
EW-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:3bHBVUUN3ME2xMlk2PjV5IN88US=> NXnrWmRDW0GQR1XS
HSC-3 NGjESGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nifmlEPTB;MT65OlM3PSEQvF2= NFTj[3RUSU6JRWK=
MLMA NFG0cG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5SmlEPTB;MT65OlY4PyEQvF2= MVHTRW5ITVJ?
RCM-1 NYLLNGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qwdmlEPTB;Mj6wNFM6QSEQvF2= NIf0RmZUSU6JRWK=
MFE-280 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLme2s6UUN3ME2yMlAzQDR6IN88US=> M3rPO3NCVkeHUh?=
ES8 M2e2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwMkW0O|Eh|ryP M2\ufXNCVkeHUh?=
TE-11 M4PM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwMkm0O|Mh|ryP M16wOnNCVkeHUh?=
HuO-3N1 NVe5[2F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xhb2lEPTB;Mj60PFc5KM7:TR?= M2eyUHNCVkeHUh?=
MHH-NB-11 M2W4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XRWmlEPTB;Mj61NVE2QCEQvF2= MnHuV2FPT0WU
TGBC11TKB MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi3NZZKSzVyPUKuOVc3QDFizszN NXjtc4FTW0GQR1XS
HOP-92 M2XKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rCRWlEPTB;Mj61PFc1OyEQvF2= NVnm[WJlW0GQR1XS
IGR-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwNkKwN|Uh|ryP Mn\4V2FPT0WU
GOTO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwNkWzO|ch|ryP NUT0RoFIW0GQR1XS
NCI-H1650 M3THXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qyOmlEPTB;Mj63NlIyPSEQvF2= NGDqSm9USU6JRWK=
NCI-H1581 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrTWVN7UUN3ME2yMlc6PjhzIN88US=> M3rC[XNCVkeHUh?=
NCI-H2405 M1jWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LiVGlEPTB;Mj64Nlc5OiEQvF2= MmnxV2FPT0WU
U-118-MG M{nzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVewT5g3UUN3ME2yMlk3PDlzIN88US=> NGnhd5lUSU6JRWK=
DoTc2-4510 NWfSZXVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjrfHpKSzVyPUOuNFE1OTdizszN MXnTRW5ITVJ?
NCI-H596 NHLRWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHKZ5Z7UUN3ME2zMlA1QTl5IN88US=> MoDQV2FPT0WU
MPP-89 NEfVXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\5emlEPTB;Mz6wOVY3PiEQvF2= MUfTRW5ITVJ?
GCIY NFn0UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTqNo17UUN3ME2zMlIxPDlzIN88US=> Mn\nV2FPT0WU
SW626 M3X3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPiSWdZUUN3ME2zMlI1PTR|IN88US=> M3r0dHNCVkeHUh?=
OCI-AML2 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVewcVhVUUN3ME2zMlMyOjd{IN88US=> M4PBWnNCVkeHUh?=
NBsusSR MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;4[GQ1UUN3ME2zMlM1QTN6IN88US=> MYHTRW5ITVJ?
AN3-CA M4W1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm0TWM2OD1|LkS0NlM5KM7:TR?= NV74enJ2W0GQR1XS
EFM-19 NETYVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\iXZhKSzVyPUOuOFg{OzlizszN M36wUHNCVkeHUh?=
RVH-421 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjEW2NKSzVyPUOuOVY5PzdizszN M4PBXHNCVkeHUh?=
5637 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\LTWM2OD1|Lk[xNVA{KM7:TR?= MW\TRW5ITVJ?
PANC-08-13 NH\TbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET3VmZKSzVyPUOuOlM1PzJizszN NYDZRZFbW0GQR1XS
H9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3STWM2OD1|Lk[3NVQ1KM7:TR?= NIHidm9USU6JRWK=
KARPAS-299 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3KTWM2OD1|Lk[3N|YyKM7:TR?= M{HmUnNCVkeHUh?=
TE-5 NVvlR3JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\Z[2lEPTB;Mz63NFcxQSEQvF2= NIjGZplUSU6JRWK=
NOS-1 NV3u[ItPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnKTWM2OD1|Lke5PFM1KM7:TR?= M1HS[XNCVkeHUh?=
HH NE\LPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv0TWM2OD1|LkizPFY5KM7:TR?= MlXCV2FPT0WU
769-P MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3TWM2OD1|Lki5OVEh|ryP NFy3dJFUSU6JRWK=
CHP-212 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7NZnllUUN3ME2zMlkzPTR7IN88US=> Mlu3V2FPT0WU
NCI-H82 NXzrNGdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjOcGxGUUN3ME2zMlk2QTN4IN88US=> NWn5PYJvW0GQR1XS
Mo-T M4n1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRwMESzNVIh|ryP MUHTRW5ITVJ?
BB65-RCC NFraOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y3XmlEPTB;ND6wOFM6QSEQvF2= MVXTRW5ITVJ?
SW1990 NYXqd3RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwMEW5NFgh|ryP M2Li[XNCVkeHUh?=
LK-2 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjPSnJ4UUN3ME20MlEyOjl|IN88US=> MoXGV2FPT0WU
ES5 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\PS4pKSzVyPUSuNVM6QDVizszN NF34NXBUSU6JRWK=
JVM-3 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwMUiyNlIh|ryP M4fveHNCVkeHUh?=
RPMI-7951 M2rlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G1WGlEPTB;ND6yNlQyOyEQvF2= MkC4V2FPT0WU
Calu-6 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTRwMke4PFEh|ryP NX7FWZlWW0GQR1XS
LC-2-ad M3rKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRwMkm1Olgh|ryP MoL0V2FPT0WU
SW954 NWKzVZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXGTWM2OD12LkK5OlYh|ryP M1nGSnNCVkeHUh?=
H-EMC-SS M{DmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvMUYdKSzVyPUSuN|E5OzFizszN NH:3eJlUSU6JRWK=
ES3 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:5c5NOUUN3ME20MlM2PDRzIN88US=> MWrTRW5ITVJ?
no-11 NY\4W25HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwM{W1OVQh|ryP NH6yXItUSU6JRWK=
LAN-6 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y1OGlEPTB;ND60OVE5QSEQvF2= NE\XTIpUSU6JRWK=
FTC-133 NFz2[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTRwNUO5OUDPxE1? MUnTRW5ITVJ?
8505C NWrW[pRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\2emhtUUN3ME20MlU1OjNizszN NHHGZnZUSU6JRWK=
SW620 NFnYNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\mTWM2OD12LkW3NFU4KM7:TR?= NXHyZnJ7W0GQR1XS
BCPAP NWnO[FFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7hTWM2OD12Lk[zOFgyKM7:TR?= M2Hhc3NCVkeHUh?=
SK-LU-1 M4fBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXI[W1KSzVyPUSuOlYxQDlizszN NEfNNGZUSU6JRWK=
NCI-H1623 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHiTWM2OD12LkewNlI5KM7:TR?= NHrsZ5pUSU6JRWK=
C2BBe1 NUW2bFlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S1dGlEPTB;ND63OFAxQCEQvF2= MkTmV2FPT0WU
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;OTpRKSzVyPUSuO|g{QDhizszN M2fWdXNCVkeHUh?=
NB6 NEjrZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnuc|ZyUUN3ME20Mlg3OjB2IN88US=> M17o[HNCVkeHUh?=
MDA-MB-157 NX\rTJB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwOEi3OkDPxE1? MlvRV2FPT0WU
UMC-11 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO3OHNDUUN3ME20Mlg5QTZ2IN88US=> Mk\NV2FPT0WU
HCC1419 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT1R25zUUN3ME20MlkxODZ|IN88US=> MkHQV2FPT0WU
NCI-H2029 NGDOe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnMTWM2OD12Lkm0NVg2KM7:TR?= MUTTRW5ITVJ?
LXF-289 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfpWm5lUUN3ME21MlA{PzF7IN88US=> NFnEZZVUSU6JRWK=
KINGS-1 MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3NGR[UUN3ME21MlA4PzR2IN88US=> MXjTRW5ITVJ?
HD-MY-Z NVTsZ2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTVwMkO5Olkh|ryP NHj4[mVUSU6JRWK=
ESS-1 NF36dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwMkW1PVch|ryP NFWwbYhUSU6JRWK=
GI-1 NHe5XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\WdVhKSzVyPUWuNlc6OjZizszN NFTGZ3NUSU6JRWK=
RPMI-2650 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTVwM{[xOkDPxE1? MV\TRW5ITVJ?
IA-LM MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD13LkO5PFcyKM7:TR?= M2PtZnNCVkeHUh?=
KP-4 M2G5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PBeWlEPTB;NT60OlM{PCEQvF2= NVO1U|FEW0GQR1XS
G-402 M1:wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTVwNUG4OlUh|ryP Mlr5V2FPT0WU
OS-RC-2 M3TjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXHbotvUUN3ME21MlUzPjB2IN88US=> MY\TRW5ITVJ?
NCI-H1155 NYrXOIU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPsTWM2OD13LkW0PVU2KM7:TR?= NGSwSVFUSU6JRWK=
OE19 NHThb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H3VmlEPTB;NT62PFYzPCEQvF2= MoTXV2FPT0WU
U-2-OS NUDS[XhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTVwOEmwNVMh|ryP NYrLZYxCW0GQR1XS
SCC-15 M1f5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTVwOUO2OlIh|ryP MWLTRW5ITVJ?
NCI-H630 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:3TWM2OD13Lkm5OFA1KM7:TR?= MVzTRW5ITVJ?
PFSK-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTZwMEWyOVkh|ryP NXfTN5djW0GQR1XS
NCI-H1770 NHLVdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTZwMkC4O|Qh|ryP M4rPPXNCVkeHUh?=
SK-MEL-3 NXrsNHoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PqNmlEPTB;Nj60NlkyPSEQvF2= M{P6UHNCVkeHUh?=
LB1047-RCC NHyyXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SyVmlEPTB;Nj60O|YzPSEQvF2= NIX0R5lUSU6JRWK=
NCI-H446 NY\qZXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZwNkK5NlUh|ryP NX3FOpZQW0GQR1XS
SW780 NF7mV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLoTWM2OD14LkewNVg2KM7:TR?= MXjTRW5ITVJ?
NEC8 NX;qcJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTZwN{[2N{DPxE1? NXfGOHBIW0GQR1XS
NOMO-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fZdmlEPTB;Nj63PFEyOSEQvF2= MX7TRW5ITVJ?
COLO-668 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZwOESzPFch|ryP NWOwd5Z2W0GQR1XS
MC116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;s[FlKSzVyPU[uPVM5QTdizszN M3jBc3NCVkeHUh?=
HCC1937 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCZ2ZKSzVyPU[uPVkzPTFizszN MmTlV2FPT0WU
NCI-N87 NXfuXYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnDS3dvUUN3ME23MlE6Ojl|IN88US=> MnfSV2FPT0WU
COLO-320-HSR NWfJ[m9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\WTWM2OD15LkKyO|M5KM7:TR?= MV\TRW5ITVJ?
HCC1806 NGOwWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTdwMk[wOFQh|ryP Mnn5V2FPT0WU
OVCAR-3 NYLlZZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXPTWM2OD15LkOzNFM5KM7:TR?= NHj3dFBUSU6JRWK=
NUGC-3 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX21WYlnUUN3ME23MlM6Pjl2IN88US=> MXTTRW5ITVJ?
SW1783 M3\Wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fOUWlEPTB;Nz60N|E4PSEQvF2= NI\UXlVUSU6JRWK=
GCT NHzvV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuTWM2OD15LkW2PVA3KM7:TR?= Mo\RV2FPT0WU
NCI-H2126 NVrWSIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTdwN{O2NlUh|ryP Mmf0V2FPT0WU
MEL-HO M3[w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwN{ewOVQh|ryP M1r2R3NCVkeHUh?=
CAPAN-1 NILIU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXuTWM2OD15Lke3N|U4KM7:TR?= MXLTRW5ITVJ?
SW756 NXzvdJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3QTWM2OD15Lke4N|M{KM7:TR?= MX7TRW5ITVJ?
SKG-IIIa NUizT41JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonXTWM2OD15LkixPFkzKM7:TR?= NXnRe2xtW0GQR1XS
HCE-T MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzUXWlKSzVyPUeuPFc4QDNizszN MoDNV2FPT0WU
Ca-Ski M2npemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGydHVZUUN3ME23Mlk6Ozh|IN88US=> MmLOV2FPT0WU
COLO-684 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;SPWlEPTB;OD6wNVgyQCEQvF2= MYjTRW5ITVJ?
KYSE-70 NEDVSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRThwMEe3Nlkh|ryP NHHlRo9USU6JRWK=
TI-73 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRThwMkW4OVEh|ryP M{fVdnNCVkeHUh?=
BT-20 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zxSWlEPTB;OD6yOlA2OiEQvF2= NFXOSnlUSU6JRWK=
MHH-ES-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO2c|RKSzVyPUiuOVE5OzRizszN MVnTRW5ITVJ?
TE-12 NEjJbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRThwNUm5N|Eh|ryP M3vue3NCVkeHUh?=
YH-13 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PPTmlEPTB;OD62NVAxQCEQvF2= NUKxN5poW0GQR1XS
SF126 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\4coZKSzVyPUiuPFM5PjVizszN NU[5[ZoyW0GQR1XS
J82 NFixeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXXTWM2OD16LkmwNFM5KM7:TR?= NG\wNJpUSU6JRWK=
RCC10RGB NUm1TnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfsN|ZkUUN3ME24Mlk6PTZzIN88US=> M1\5OnNCVkeHUh?=
SK-UT-1 NHzGVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G3XWlEPTB;OT6wOFk1PSEQvF2= M1rFRXNCVkeHUh?=
LB2241-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxN4JKSzVyPUmuNVkyOzdizszN NF;QflVUSU6JRWK=
LB996-RCC NEL2dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DTNWlEPTB;OT6xPVg6KM7:TR?= M{XVenNCVkeHUh?=
EPLC-272H NFLYdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTlwM{e2OVch|ryP NVvxTY5EW0GQR1XS
CTV-1 NV36WIpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOyW|BKSzVyPUmuOVY2OzJizszN MnPYV2FPT0WU
HSC-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrPRZJKSzVyPUmuOVc2PSEQvF2= NX;2NmZsW0GQR1XS
SK-MEL-28 NFrmVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXtVZBKSzVyPUmuOlE5QTNizszN MU\TRW5ITVJ?
MMAC-SF NV7i[45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Tm[GlEPTB;OT62PFc2KM7:TR?= MlTtV2FPT0WU
CP50-MEL-B MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWM2OD17Lke1O|gzKM7:TR?= MoezV2FPT0WU
HT-1080 NFrtcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zSmlEPTB;OT63O|c{QSEQvF2= Mke2V2FPT0WU
HEC-1 NG\pOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHz[npKSzVyPUGwMlM{PTJizszN MlH5V2FPT0WU
AGS NV\PT|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf3TWM2OD1zMD6zO|Qh|ryP NFHxOZNUSU6JRWK=
GAMG NYrkT4xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[0TWM2OD1zMD61NVYzKM7:TR?= MV\TRW5ITVJ?
SW48 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPSTWM2OD1zMD61NVg6KM7:TR?= MWDTRW5ITVJ?
U031 M2LCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTrWXhKSzVyPUGwMlU6ODhizszN M4S5eHNCVkeHUh?=
OVCAR-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFyLk[0Nlkh|ryP MXHTRW5ITVJ?
SF295 M2nyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD1zMD62O|A1KM7:TR?= NXTYXZpOW0GQR1XS
BHT-101 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILydXNKSzVyPUGwMlcyPzdizszN MWXTRW5ITVJ?
VMRC-RCZ M2jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\5WIhKSzVyPUGxMlMzODFizszN MVHTRW5ITVJ?
ACHN NEHWSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fTUWlEPTB;MUGuOFIyOSEQvF2= Mo\ZV2FPT0WU
NCI-H526 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:0UnVKSzVyPUGxMlUxPDNizszN MVjTRW5ITVJ?
MN-60 M4jXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezTIpKSzVyPUGxMlU{QSEQvF2= NFnLS|dUSU6JRWK=
NCI-H2291 NXizSXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKxTWM2OD1zMT61OFY3KM7:TR?= NHrPV3JUSU6JRWK=
SCC-25 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrXbnNrUUN3ME2xNU44PTV4IN88US=> MXvTRW5ITVJ?
SK-MEL-2 NFPEcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCyS2RjUUN3ME2xNU44PjN5IN88US=> MWPTRW5ITVJ?
SN12C MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;SNmlEPTB;MUGuPVM2PSEQvF2= M{SxO3NCVkeHUh?=
NCI-H69 M4OxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXmTWM2OD1zMj60NlM1KM7:TR?= NULH[opWW0GQR1XS
ME-180 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PseWlEPTB;MUKuO|A2PCEQvF2= NWf0UJNkW0GQR1XS
MC-IXC Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHZTWM2OD1zMj63OVE5KM7:TR?= MXLTRW5ITVJ?
NCI-H2347 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jvbmlEPTB;MUKuO|YyPCEQvF2= MVLTRW5ITVJ?
M059J NXHCeGJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDOGlKSzVyPUGyMlc4OjdizszN NEfnV2lUSU6JRWK=
A2058 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLtTWM2OD1zMj64OlgyKM7:TR?= MWDTRW5ITVJ?
VA-ES-BJ M3[zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfTWJdKSzVyPUGyMlg4QDVizszN MljrV2FPT0WU
Ca9-22 NWDkWVZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i5eWlEPTB;MUKuPVQ2OSEQvF2= MVTTRW5ITVJ?
KNS-42 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HCbmlEPTB;MUKuPVk5PCEQvF2= Mle3V2FPT0WU
LoVo MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3bGlEPTB;MUOuNlMyOyEQvF2= NVLpToNPW0GQR1XS
AM-38 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XMV2lEPTB;MUOuNlU3PiEQvF2= NWPNRolqW0GQR1XS
NB5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPKXVV{UUN3ME2xN{4{PzV{IN88US=> MXjTRW5ITVJ?
L-363 M3nxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF|LkSwN|Mh|ryP NI\kdZdUSU6JRWK=
SK-MEL-30 NFfVTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfLSnkxUUN3ME2xOE4xPjR3IN88US=> NHO2V|ZUSU6JRWK=
NCI-H1563 Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILMclJKSzVyPUG0MlYxOzlizszN NFrlcm9USU6JRWK=
NCI-H2228 NX3pXHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDweWRKSzVyPUG0MlYxPzdizszN MV7TRW5ITVJ?
MFM-223 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXSVZFKSzVyPUG1MlE5OTNizszN NFHsc5hUSU6JRWK=
LB831-BLC MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[xOJJEUUN3ME2xOU4zPzZ5IN88US=> NVfiPZE2W0GQR1XS
SW872 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLFZYZKSzVyPUG1MlMxQDZizszN NH[2XWJUSU6JRWK=
NCI-H522 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHvTWM2OD1zNT6zN|A3KM7:TR?= MULTRW5ITVJ?
EW-1 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF3LkW0OlIh|ryP NFr6enVUSU6JRWK=
HN Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF3LkW5OFIh|ryP NY\ue3pHW0GQR1XS
SW837 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF3Lke4OFch|ryP M4Tsc3NCVkeHUh?=
SCC-9 NFTUc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGxOGg5UUN3ME2xOU45OTF2IN88US=> MXfTRW5ITVJ?
MKN7 NXe1NmVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TJPGlEPTB;MUWuPVc{OiEQvF2= M4HsTHNCVkeHUh?=
KYSE-410 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VOINKSzVyPUG2MlU6OSEQvF2= MnHUV2FPT0WU
SK-N-DZ MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq3TWM2OD1zNj62NVE3KM7:TR?= M3PTU3NCVkeHUh?=
COR-L105 NXTqVZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PHZmlEPTB;MU[uOlUzQCEQvF2= NGXGcmFUSU6JRWK=
LB2518-MEL MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF4LkizPFkh|ryP MoLrV2FPT0WU
OVCAR-4 NIfxbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\icGlRUUN3ME2xOk45QDZ{IN88US=> NVH1fGc1W0GQR1XS
TK10 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fpXmlEPTB;MU[uPVQ4OyEQvF2= MVTTRW5ITVJ?
KNS-62 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF4Lkm3O|ch|ryP MkDBV2FPT0WU
RPMI-8866 NFrGNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nKVmlEPTB;MUeuNVc{OiEQvF2= MmfSV2FPT0WU
HuP-T4 NGP4SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\OVZVKSzVyPUG3MlI1QTVizszN Mln6V2FPT0WU
CGTH-W-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[zTWM2OD1zNz61NlE6KM7:TR?= MX\TRW5ITVJ?
T-24 NF\wO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP0b2ZYUUN3ME2xO{42OzR5IN88US=> NEnWPXlUSU6JRWK=
HT-3 NGqwT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnOTJhKSzVyPUG3MlU6OTRizszN NG\oUWlUSU6JRWK=
KS-1 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWyOm5wUUN3ME2xO{43PzNizszN NIPxfHdUSU6JRWK=
NCI-H1792 M{Da[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHBUJJKSzVyPUG3Mlc6QCEQvF2= MmTJV2FPT0WU
ABC-1 NGf6[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rRRWlEPTB;MUeuPFE1OSEQvF2= NEHYO|ZUSU6JRWK=
BPH-1 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PoO2lEPTB;MUiuNVY5PSEQvF2= MVrTRW5ITVJ?
A431 M3nCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq4UWNKSzVyPUG4MlQyOjdizszN MkjYV2FPT0WU
T98G MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF6LkWxOVch|ryP MXnTRW5ITVJ?
BHY MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF6Lki2PUDPxE1? M1LiRXNCVkeHUh?=
Capan-2 NWq1T|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y0[mlEPTB;MUiuPVA4QCEQvF2= NGK2PFZUSU6JRWK=
MDA-MB-175-VII M2nESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF6LkmyNFkh|ryP NUj6OlU6W0GQR1XS
CAL-27 NHr6XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF7LkC0PFch|ryP MorEV2FPT0WU
AsPC-1 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlniTWM2OD1zOT64OlU4KM7:TR?= NH\wW5FUSU6JRWK=
KU812 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T0OWlEPTB;MUmuPVU4OyEQvF2= NFrkdnBUSU6JRWK=
NCI-H441 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTSTWM2OD1{MD6wNFEh|ryP NFj3NJJUSU6JRWK=
Mewo MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJyLkGyPFgh|ryP MmfHV2FPT0WU
SK-MEL-24 M4X3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUftR2NKUUN3ME2yNE4yPDd5IN88US=> MlPxV2FPT0WU
NCI-H727 NFnuUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnTNWQzUUN3ME2yNE4zPzB2IN88US=> MXrTRW5ITVJ?
EKVX MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLuTWM2OD1{MD62NFYh|ryP NVz5ZoRJW0GQR1XS
RT-112 NISwVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r0OmlEPTB;MkCuOlEzOiEQvF2= Mmf1V2FPT0WU
CAMA-1 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HYTmlEPTB;MkCuPVgxOyEQvF2= M{XnRnNCVkeHUh?=
SW900 M2TD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xNWlEPTB;MkGuNFE1QSEQvF2= NGfpfmVUSU6JRWK=
NCI-H23 M3LYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[wTWM2OD1{MT6xNlc4KM7:TR?= MlTIV2FPT0WU
SK-PN-DW NGLN[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzsTWM2OD1{MT6xOlQ6KM7:TR?= MmruV2FPT0WU
BB30-HNC Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv1Wo9KSzVyPUKxMlI4PDVizszN MlX3V2FPT0WU
VM-CUB-1 NXfCfpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJzLkO1N|Yh|ryP MoLDV2FPT0WU
IST-MEL1 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWzWoZ{UUN3ME2yNU4{Pjl{IN88US=> NGjjUWJUSU6JRWK=
CTB-1 NVfrd5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XESmlEPTB;MkGuOFc2PSEQvF2= M4XsfHNCVkeHUh?=
LCLC-103H M1u4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW4VllHUUN3ME2yNk4yPTh{IN88US=> Mn3tV2FPT0WU
PANC-03-27 NVfQTJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPvSYFHUUN3ME2yNk42OTZ7IN88US=> MWfTRW5ITVJ?
HTC-C3 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfpfY9JUUN3ME2yNk42PTV3IN88US=> Ml7GV2FPT0WU
TE-8 NXnTc5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTwTWM2OD1{Mz6yOVY2KM7:TR?= NFfPS3dUSU6JRWK=
NCI-H292 M4D5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nOZmlEPTB;MkWuN|U{PiEQvF2= NFjJWmRUSU6JRWK=
COLO-680N NWTT[GFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\VUGlEPTB;MkWuOlMzQSEQvF2= NXmwWmRoW0GQR1XS
KYSE-520 NULFbFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\OXGlEPTB;MkWuOlQ1KM7:TR?= MW\TRW5ITVJ?
NB10 M{Hm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jpV2lEPTB;Mk[uN|EyPyEQvF2= M1fZdHNCVkeHUh?=
NCI-H661 NWP5T|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLBTWM2OD1{Nj60O|E{KM7:TR?= NVeydlFNW0GQR1XS
GMS-10 NUTONVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ4Lki2N|gh|ryP NVvOdXdRW0GQR1XS
NCI-H2122 M3LEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX3TWM2OD1{Nj65PVk5KM7:TR?= MlXRV2FPT0WU
OVCAR-8 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvkVGpnUUN3ME2yO{4xPjN6IN88US=> Mn21V2FPT0WU
DJM-1 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG2c4hNUUN3ME2yO{4yPDV2IN88US=> M4LVXHNCVkeHUh?=
UACC-893 NFrhNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULJXng2UUN3ME2yO{46QDd6IN88US=> MXvTRW5ITVJ?
C8166 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7RTWM2OD1{OD62PVM5KM7:TR?= MnfHV2FPT0WU
NCI-H1693 NIDFPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXhVVBWUUN3ME2yPE43QTd3IN88US=> MnzyV2FPT0WU
TYK-nu MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNyLkCzOFUh|ryP NU\OcJhHW0GQR1XS
SW1710 NHe2R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNyLkGyOkDPxE1? NXLsNIlLW0GQR1XS
A375 M1m3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv1XYRKSzVyPUOwMlMzPDNizszN NYi3XGplW0GQR1XS
HMV-II M3e2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDJTWM2OD1|MT6zOVkzKM7:TR?= MV\TRW5ITVJ?
NCI-H2087 M4nnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXFUYRtUUN3ME2zNU43OzV{IN88US=> NVO1dpBsW0GQR1XS
CAL-54 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNzLkeyOFEh|ryP M4\yOXNCVkeHUh?=
HCC70 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrBTWM2OD1|Mj6xN|g4KM7:TR?= NVrnW2Y4W0GQR1XS
ES1 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnVd4E4UUN3ME2zNk4{ODZ{IN88US=> MYDTRW5ITVJ?
NCI-H1355 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5cWlEPTB;M{OuNlA1KM7:TR?= NVOwVnlXW0GQR1XS
CFPAC-1 NES4dHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnITWM2OD1|Mz6yN|MzKM7:TR?= NXvxUWp6W0GQR1XS
MKN28 M2LGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[1e2lEPTB;M{OuN|gxQSEQvF2= NI\qV2tUSU6JRWK=
HDLM-2 M4SwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN|Lk[5N|Eh|ryP MlfFV2FPT0WU
PANC-10-05 M1jobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOxNHRKSzVyPUO0MlExOTRizszN MoO3V2FPT0WU
SAS MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrqUJJKSzVyPUO0MlQ2PjVizszN NHz3UYJUSU6JRWK=
HCC1395 NFHmd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rLXmlEPTB;M{SuO|E5PiEQvF2= Ml7uV2FPT0WU
8305C MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT4RmtKSzVyPUO1Mlg1OTVizszN MmTtV2FPT0WU
KM12 NHzZNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN4Lke1OFch|ryP M2fVeHNCVkeHUh?=
SW1116 NXr2TolGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPJUoZKSzVyPUO3MlU6QTJizszN NUTWT3c2W0GQR1XS
SK-MEL-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN6LkOzPFkh|ryP NG\aeYVUSU6JRWK=
HCC2218 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPMTWM2OD1|OD62OVE6KM7:TR?= MlfwV2FPT0WU
T84 NVzUXZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN6Lke0NFkh|ryP M3zoNHNCVkeHUh?=
ETK-1 M2K3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD1|OT6wNlIh|ryP MlOzV2FPT0WU
COLO-800 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O4UGlEPTB;M{muN|g3QCEQvF2= NGfBSHBUSU6JRWK=
CAL-12T NW\VRVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\WTWM2OD1|OT61NlgyKM7:TR?= M17FfXNCVkeHUh?=
ACN NHTrbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRyLkS5NVEh|ryP MWLTRW5ITVJ?
SJSA-1 NFLmb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPSTWM2OD12MT6xOVk3KM7:TR?= MWHTRW5ITVJ?
PSN1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXoOpZKSzVyPUSxMlE4PDlizszN NFfYOXlUSU6JRWK=
D-566MG MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GxPWlEPTB;NEGuNlA5PiEQvF2= MlPGV2FPT0WU
EGI-1 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR{LkSyPEDPxE1? Ml\CV2FPT0WU
A204 NWDBdYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmTWM2OD12Mj62N|g5KM7:TR?= MXjTRW5ITVJ?
Saos-2 NF\UepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTR{LkizOlkh|ryP M1PkSHNCVkeHUh?=
SNU-C2B NEXLfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknNTWM2OD12Mz62PFc5KM7:TR?= NV64eVFsW0GQR1XS
HLE NHXZPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fBR2lEPTB;NESuNFg2PiEQvF2= Mlm2V2FPT0WU
SW1463 NX3VNVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWwbZdKSzVyPUS0Mlk6PzFizszN MUnTRW5ITVJ?
DSH1 NYXOOG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;nfHp4UUN3ME20OU4xODN|IN88US=> M2D6bHNCVkeHUh?=
MCF7 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Td|hKSzVyPUS1MlUxPTFizszN MmCxV2FPT0WU
K5 NF;uZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTR3Lkm0NFUh|ryP MoS3V2FPT0WU
NCI-H358 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;qcW0zUUN3ME20O{4zOTVizszN MmPkV2FPT0WU
NCI-H2030 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj4fpJOUUN3ME20O{4zOzd2IN88US=> M2P1XnNCVkeHUh?=
SW948 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;aTWM2OD12Nz60OlQh|ryP NVPDWXZCW0GQR1XS
BALL-1 NELoe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ib5V{UUN3ME20O{43OTZ6IN88US=> NFPaS3NUSU6JRWK=
TE-9 NXXpdlZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[1TWM2OD12Nz65OVgyKM7:TR?= M3fwSHNCVkeHUh?=
SK-N-FI M{LoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPBOog{UUN3ME20PE4xOzV6IN88US=> NYS3W4FMW0GQR1XS
KALS-1 NWPSOFBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDB[ZBDUUN3ME20PE4yOjh7IN88US=> NHfTTZRUSU6JRWK=
HO-1-N-1 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TmZ2lEPTB;NEiuO|Q1PSEQvF2= NYjIUI9TW0GQR1XS
NCI-H2452 M2XlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTR7LkGxOVIh|ryP M{D6[nNCVkeHUh?=
OC-314 NXHn[JVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLKTWM2OD12OT62PFM1KM7:TR?= NYLSZlhVW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

プロトコル(参考用のみ)

キナーゼアッセイ:

[1]

+ 展開

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
細胞アッセイ:

[1]

+ 展開
  • 細胞株: SCLC cell lines
  • 濃度: 0-1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (参考用のみ)
動物実験:

[1]

+ 展開
  • 動物モデル: C.B.-17 scid-bg or C.B.-17 scid mice
  • 製剤: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • 投薬量: 100 mg/kg/d
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 5% DMSO+corn oil 7mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • 回答:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • 問題2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • 回答:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2信号経路図

Bcl-2 Inhibitors with Unique Features

相関Bcl-2製品

Tags: Navitoclax (ABT-263)を買う | Navitoclax (ABT-263) ic50 | Navitoclax (ABT-263)供給者 | Navitoclax (ABT-263)を購入する | Navitoclax (ABT-263)費用 | Navitoclax (ABT-263)生産者 | オーダーNavitoclax (ABT-263) | Navitoclax (ABT-263)化学構造 | Navitoclax (ABT-263)分子量 | Navitoclax (ABT-263)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID